Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Protein > TIGIT > TIT-H5253

Human TIGIT Protein, Mouse IgG2a Fc Tag, low endotoxin (MALS verified)

Order Now

  • Synonym
    TIGIT,VSIG9,VSTM3
  • Source
    Human TIGIT, Mouse IgG2a Fc Tag(TIT-H5253) is expressed from human 293 cells (HEK293). It contains AA Met 22 - Pro 141 (Accession # Q495A1-1).
    Predicted N-terminus: Met 22
  • Molecular Characterization
    TIGIT Structure

    This protein carries a mouse IgG2a Fc tag at the C-terminus.

    The protein has a calculated MW of 40.1 kDa. The protein migrates as 45-50 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

  • Endotoxin
    Less than 0.1 EU per μg by the LAL method.
  • Purity

    >95% as determined by SDS-PAGE.

    >90% as determined by SEC-MALS.

  • Formulation

    Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

    Contact us for customized product form or formulation.

  • Reconstitution

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • Storage

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 12 months in lyophilized state;
    2. -70°C for 3 months under sterile conditions after reconstitution.
SDS-PAGE
TIGIT SDS-PAGE

Human TIGIT, Mouse IgG2a Fc Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.

SEC-MALS
TIGIT MALS images

The purity of Human TIGIT, Mouse IgG2a Fc Tag (Cat. No. TIT-H5253) is more than 90% and the molecular weight of this protein is around 80-105 kDa verified by SEC-MALS.

Bioactivity-ELISA
 TIGIT ELISA

Immobilized Human CD155, Fc Tag (Cat. No. CD5-H5251) at 5 μg/mL (100 μL/well) can bind Human TIGIT, Mouse IgG2a Fc Tag (Cat. No. TIT-H5253) with a linear range of 0.5-4 ng/mL (QC tested).

 TIGIT ELISA

Serial dilutions of TIGIT Antibody (1:2 serial dilutions, from 20 μg/mL to 0.0097 μg/mL) were added into Human TIGIT, Mouse IgG2a Fc Tag (Cat. No. TIT-H5253): Biotinylated Human Nectin-2, Fc,Avitag (Cat. No. CD2-H82F8) binding reactions. The assay was performed according to the above described protocol. Background was subtracted from data points before curve fitting.

Bioactivity-BLI
 TIGIT BLI

Loaded Human TIGIT, Mouse IgG2a Fc Tag (Cat. No. TIT-H5253) on Protein A Biosensor, can bind Human CD155, His Tag (Cat. No. CD5-H5223) with an affinity constant of 0.92 μM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

Bioactivity-FACS
 TIGIT FACS

FACS assay shows that Human TIGIT, Mouse IgG2a Fc Tag (Cat. No. TIT-H5253) can bind to 293T cell overexpressing human CD155. The concentration of TIGIT used is 0.03 μg/mL (Routinely tested).

  • Background
    T-cell immunoreceptor with Ig and ITIM domains (TIGIT) is also known as V-set and immunoglobulin domain-containing protein 9 (VSIG9), V-set and transmembrane domain-containing protein 3 (VSTM3),which belongs to single-pass type I membrane protein containing an immunoglobulin variable domain, a transmembrane domain and an immunoreceptor tyrosine-based inhibitory motif (ITIM). TIGIT is expressed at low levels on peripheral memory and regulatory CD4+ T-cells and NK cells and is up-regulated following activation of these cells (at protein level). TIGIT binds with high affinity to the poliovirus receptor (PVR) which causes increased secretion of IL10 and decreased secretion of IL12B and suppresses T-cell activation by promoting the generation of mature immunoregulatory dendritic cells.
  • Clinical and Translational Updates

Comments (0)


ETA of in-stock products: 2 business days

Price(USD) : $350.00

Price(USD) : $2540.00

Promotion & Exhibitions



Drug Development Status

  • Number of Launched Drugs:0 Details
  • Number of Drugs in Clinical Trials:38 Details
  • Latest Research Phase:Phase 3 Clinical

Datasheet & Documentation

Request for DMF
DMF (Drug Master File)

Related Products

New Product Launch

Questions & Comments

This web search service is supported by Google Inc.

totop
Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message